ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection
Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Segments 2A and 2B of this trial evaluate the safety, efficacy, pharmacokinetics, fecal
concentrations, and fecal microbiome effects of ACX-362E [ibezapolstat] in patients with C.
difficile infection (CDI).